Thermostable vaccines could replace up to 20% of the global vaccine market within the next decade.
In 2021, WHO reported 94 vaccine distributors globally, with China (23) and India (7) leading the Western Pacific region, representing 32% of its manufacturers. Overall, 41% of vaccine producers were based in this region.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5117
The World Health Organization (WHO) estimates that immunization saves 3.5–5 million lives annually by preventing diseases like diphtheria, tetanus, pertussis, influenza, and measles. However, cold storage challenges often lead to vaccine damage, limiting their effectiveness. Thermostable vaccines offer a breakthrough by remaining stable at room temperature for extended periods, eliminating the need for costly cold chain logistics. This innovation reduces storage and transportation expenses, making large-scale immunization efforts more affordable and accessible.
Unlike traditional vaccines that require strict refrigeration to retain their potency, thermostable vaccines are designed to withstand temperature fluctuations. This is particularly valuable in regions with limited refrigeration infrastructure, such as remote areas or during emergencies. By overcoming logistical hurdles, thermostable vaccines expand access to life-saving immunizations, ensuring that underserved communities can benefit from vaccination programs.
Tuberculosis (TB) remains a significant global health challenge, spreading through the air when infected individuals breathe out bacteria. In 2021, TB caused 1.6 million deaths and affected 10.6 million people, with nearly two billion people carrying TB bacteria. Thermostable vaccines could play a vital role in managing this disease, especially in areas with inadequate refrigeration.
In March 2023, the Access to Advanced Health Institute (AAHI) announced promising results from a Phase I clinical trial for a novel thermostable TB vaccine. This vaccine targets Mycobacterium tuberculosis, the bacteria responsible for TB, using a fusion protein (ID93) combined with a specialized immune-boosting adjuvant (GLA-SE). Presented in a freeze-dried form, the vaccine does not require refrigeration, making it a game-changer in TB prevention and control.
While there are no FDA-approved vaccines that are entirely thermostable and free from refrigeration requirements, some vaccines have been developed with enhanced thermal stability. These vaccines can tolerate higher temperatures for longer periods without losing effectiveness, making them more practical for areas with limited refrigeration access.
Thermostable vaccines are a major step forward in vaccine technology. By reducing dependence on cold chain logistics, they address storage and transportation challenges, improving global vaccination efforts. These advancements ensure vaccines remain effective in difficult conditions, helping to protect more people from preventable diseases and advancing global public health.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/thermostable-vaccine-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5117
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
Kedrion Biopharma has announced that its human coagulation factor X concentrate, COAGADEX®, has been granted orphan drug designation by the… Read More
enecard PBF, a pioneer in pharmacy benefit facilitation, has announced a strategic partnership with DecisionRX, Inc., a leader in medication… Read More
In a high-stakes biotech industry where drug development can span over a decade, four small but determined biotech companies are… Read More
cell-free DNA and precision medicine, has officially announced the launch of the TEODOR trial (ABCSG 61), a groundbreaking phase 2,… Read More
The global interventional radiology market is witnessing rapid expansion, driven by advancements in minimally invasive procedures, rising demand for diagnostic… Read More
The global physical therapy market is valued at USD 28.06 billion in 2024, growing to USD 29.18 billion in 2025… Read More